[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
August 1989

MK-927: A Topically Effective Carbonic Anhydrase Inhibitor in Patients

Author Affiliations

From the Department of Ophthalmology, Besançon (France) University (Drs Bron and Royer); the Departments of Clinical Research (Dr Lippa), Clinical Pharmacology (Dr Brunner-Ferber), and Biostatistics (Ms Panebianco), Merck Sharp & Dohme Research Laboratories, West Point, Pa; and the Department of Ophthalmology, Technical University of Munich (West Germany) (Drs Hofmann, Feicht, and Von Denffer).

Arch Ophthalmol. 1989;107(8):1143-1146. doi:10.1001/archopht.1989.01070020209026

• The effects on intraocular pressure of the novel topical carbonic anhydrase inhibitor MK-927 were investigated for the first time in patients. Three drops of 2% MK-927 was administered in a two-center, double-masked, randomized, placebocontrolled, two-period crossover study in 25 patients with bilateral primary open angle glaucoma or ocular hypertension. At 4.5 hours after the dose, MK-927-treated eyes demonstrated a peak mean change of −7.7 mm Hg from a mean intraocular pressure of 27.8 mm Hg immediately before the dose; this compares with a change of −3.9 mm Hg from a mean intraocular pressure of 28.2 mm Hg when the same eyes were treated with placebo. The peak mean percent change in intraocular pressure in eyes treated with MK-927 was −26.7% at 6 hours after the dose compared with a change of −13.7% after treatment with placebo. No contralateral effect on intraocular pressure due to MK-927 was observed.